Trials / Recruiting
RecruitingNCT07439250
A Study of Olomorasib (LY3537982) in Healthy Participants
A Phase 1, Open-Label, Fixed-Sequence Study to Investigate the Effect of Fluconazole on the Pharmacokinetics of Olomorasib (LY3537982) in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overnight stays in the research center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olomorasib | Administered orally |
| DRUG | Fluconazole | Administered orally |
Timeline
- Start date
- 2026-03-02
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2026-02-27
- Last updated
- 2026-03-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07439250. Inclusion in this directory is not an endorsement.